06 jul: FormueEvolution I – indre værdi den 6. juli 2012
06 jul: Formuepleje Safe A/S indre værdi: 188,5 pr. aktie.
06-07-2012 09:39:46

Spar Nord upgrades its forecast for full-year earnings and loan impairment

Relateret indhold
03 mar - 
Tirsdagens aktier: Genmab belønnet, Veloxis og Mols str..
03 mar - 
Aktier/middag: Genmab forrest i forholdsvis stille mark..
03 mar - 
Aktier/åbning: C20 lidt ned trods stigning i Genmab
Relateret debat
03 mar - 
SNB er vist steget 2 kr. i dag. Se andet indlæg i dag -..
26 feb - 
Tror det bliver delvis til afskrivninger og udbytte. De..
26 feb - 
Så er det formentlig i aften fusionen mellem Nørresundb..

Spar Nord upgrades its forecast for full-year earnings and loan impairment

Forecast for core earnings before impairment revised upwards to the DKK 900

million range

In light of business developments in H1 2012, Spar Nord upgrades its forecast

for full-year core income by approx DKK 100 million.

The primary reason for this upward revision is growth in activity-related

earnings, triggered in part by major remortgaging activity in the mortgage

credit area. To this should be added positive market-value adjustments of the

Bank’s bond portfolio as a result of the low interest level.

Costs and expenses are still expected to end at the same level as in 2011, for

which reason the forecast for full-year core earnings before impairment is

upgraded from around DKK 800 million to around DKK 900 million.

Extraordinary impairment of DKK 96 million as result of revised guidelines from

the Danish Financial Supervisory Authority

After having reviewed the Bank’s lending portfolio, Spar Nord expects the

Bank’s loan impairment provisions, etc. in Q2 2012 to be about DKK 115 million

higher than in Q1 2012.

DKK 96 million of the increase on Q1 is attributable to a more specific

formulation of the guidelines issued by the Danish Financial Supervisory

Authority regarding the valuation of collateral for facilities granted to

customers in the property and agricultural sectors.

Thus, DKK 45 million of the increase is attributable to facilities granted to

customers in the property sector - specifically to the changed valuation of

collateral provided in connection with development projects.

The balance of DKK 51 million is attributable to lending to the agricultural

sector - specifically to higher standard realisation costs in connection with

forced sales and a lower valuation of production equipment and foreign assets.

In light of the extraordinary nature of the impairment provisions in Q2, the

Bank expects loan impairment to bounce back to the Q1 level, starting from Q3

2012.

Interim Report for the first six months

Spar Nord’s Interim Report for H1 2012 will be published on 15 August as

scheduled.

Please direct any enquiries you may have to Lasse Nyby, Chief Executive

Officer, at tel.+45 9634 4011, or Ole Madsen, Senior Vice President, Corporate

Communications, at tel. +45 9634 4010.

Sincerely yours,

Spar Nord Bank A/S

Ole Madsen

Senior Vice President, Corporate Communications

Direct ext: +45 9634 4010

oma@sparnord.dk

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo: Analytikerne skruer op for forventningerne efter regnskab

03-03-2015 15:29:30
Analytikerne er i samlet flok blevet endnu mere positivt indstillet over for Novo Nordisks potentiale i de kommende år efter årsregnskabet for 2014 fra medicina..

Genmab/Jyske: Lægger ekstra 60 kr. til kursmålet

03-03-2015 13:09:35
Der var ikke meget nyt i Genmabs regnskab for fjerde kvartal, vurderer Jyske Bank, der dog alligevel løfter kursmålet for biotekaktien med 60 kr. til 570 efter ..

Aktier/åbning: C20 lidt ned trods stigning i Genmab

03-03-2015 09:22:04
Det danske aktiemarked startede tirsdag i et lille plus, men efter et kvarters handel har markedet taget en negativt drejning. Eliteindekset C20 Cap ligger ved ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Analytikerne skruer op for forventningerne efter regnskab
2
Eivind Kolding tror på godt afkast af NNIT - avis
3
Novo: Eksperter taler konkurrents nye insulinmiddel ned
4
Genmab/Jyske: Lægger ekstra 60 kr. til kursmålet
5
Genmab indregner milepæle fra Daratumumab-ansøgninger

Relaterede aktiekurser

Spar Nord Bank A/S 63,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
4. marts 2015 05:19:38
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB7 - 2015-03-04 05:19:38 - 2015-03-04 05:19:38 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x